American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
The pharmacology and pharmacokinetics of the antidepressant vilazodone (approved for U.S. marketing in 2011) are reviewed, with an emphasis on efficacy and safety data from Phase III clinical trials. ⋯ Vilazodone is an efficacious and safe new antidepressant for the treatment of MDD. Its relatively high cost and adverse-effect profile, as well as a lack of data demonstrating that vilazodone can produce long-term MDD remission and offer significant advantages over the current standard of care, may limit the usefulness of vilazodone in clinical practice.
-
Am J Health Syst Pharm · Sep 2012
Evaluation of appropriate serologic testing for suspected heparin-induced thrombocytopenia.
The predictive value of clinical "4-T's" scoring in patient selection for serologic testing to confirm suspected heparin-induced thrombocytopenia (HIT) was evaluated. ⋯ The study results suggest that among patients whose 4-T's scores indicate a low probability of HIT, the results of subsequent ELISA testing for HIT antibodies are likely to be negative in about 8 of 10 cases.